Montérégie Integrated Cancer Center , part of Charles-LeMoyne Hospital , is a center of excellence and recognized leader in the treatment of cancer in the province of Quebec The Radixact System is equipped with ClearRT™ and Synchrony ® , advanced technologies designed to improve treatment outcomes
New System Will Play a Key Role in Delivering Radiation Treatments in One of the Largest Cancer Facilities in Washington State MADISON, Wis. , Jan. 25, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Providence Swedish Radiosurgery Center in Seattle, Washington is
Erectile Function Preserved in More Than 80 Percent of Patients SUNNYVALE, Calif., Oct 01, 2009 /PRNewswire-FirstCall via COMTEX/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer
ASTRO Selects the Data for Center Stage at Largest Annual Meeting of Radiation Oncologists SUNNYVALE, Calif. , Sept. 27, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective, 21 center study showed 97 percent of low- and intermediate-risk prostate
SUNNYVALE, Calif., July 6, 2010 /PRNewswire via COMTEX/ -- Results Presented in Spine, Lung, Liver and Prostate Treatment Emphasized the Benefits of Whole Body Radiosurgery Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, today announced highlights from the Third
The CyberKnife System, with its Unique Ability to Track and Correct for Motion During Treatment, Demonstrates Strong Results in Prostate Cancer SUNNYVALE, Calif. , Nov. 5, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today clinical
Benefits of Frameless Delivery and Fractionation Demonstrated in Favorable Response Rates and Hearing Preservation SUNNYVALE, Calif ., May 5 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that significant clinical data
Data Presented at the 2019 Genitourinary Cancers Symposium Reinforces Benefits of Short Course of Treatment Using Stereotactic Body Radiation Therapy for Low- or Intermediate-Risk Prostate Cancer SUNNYVALE, Calif. , Feb. 22, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today
SUNNYVALE, Calif. , April 21, 2022 /PRNewswire/ -- When Al Gold , the owner of the Arkansas Derby winner Cyberknife, received a diagnosis of prostate cancer, he was determined to find a potential cure for his disease while minimizing the impact of treatment on his daily life. Mr.
Hospital Adds Accuray ClearRT™ Helical Fan-Beam kVCT Imaging and Synchrony ® Technologies to Both Radixact Systems, Creating the Ultimate System for Personalized Cancer Care SUNNYVALE, Calif. , Nov. 16, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Oscar Lambret
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.